Xarelto, Pradaxa Difficult To Separate After Positive NICE Final Guidance
This article was originally published in The Pink Sheet Daily
Executive Summary
Bayer’s Xarelto has made it into the NHS in England after its NICE recommendation went unchallenged, prompting a head to head battle with Boehringer Ingelheim’s Pradaxa.
You may also be interested in...
NICE Pans Pomalidomide For Blood Cancer, Backs Xarelto In ACS Patients
U.K. HTA rejects Celgene’s pomalidomide for treating multiple myeloma on cost grounds but waves through Bayer’s rivaroxaban for preventing blood clots in people who have had a heart attack.
NICE Clears Pradaxa For DVT, Setting Up Another Clash With Xarelto
NICE has given the thumbs up to Boehringer Ingelheim's Pradaxa in deep vein thrombosis and pulmonary embolism, which means the drug is now set to battle Bayer's Xarelto for market share in this indication.
Eliquis Gets NICE Final Nod But Fails to Outrun The Competition
NICE has cleared a path for Bristol-Myers Squibb’s Eliquis to be included on the British National Health System, but said the data supplied were not robust enough to differentiate the drug from its competition.